Biogen Avonex new patients: 50% are treatment-naive, CEO Vincent tells Hambrecht & Quist.
Executive Summary
BIOGEN AVONEX SALES GROWTH: TREATMENT-NAIVE PATIENTS ACCOUNT FOR 50% of new prescriptions for Avonex (interferon beta-1a), Biogen CEO James Vincent said Jan. 7 at the Hambrecht & Quist health care conference in San Francisco. About one-third of new scripts are for patients switching from Chiron/Berlex Betaseron (interferon beta-1b) and about one-fifth are for patients who used Betaseron but quit, Vincent said. "Approximately two-thirds of our sales are expanding the total market of patients on drug," he stated.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth